...
【24h】

Is there a benefit of peritoneal drainage for necrotizing enterocolitis in newborn infants?

机译:腹膜引流对新生儿坏死性小肠结肠炎有好处吗?

获取原文
获取原文并翻译 | 示例

摘要

Primary peritoneal drainage in infants with perforated necrotizing enterocolitis (NEC) has been used for many years [1-3]. Pediatric surgeons have viewed peritoneal drainage as a definitive treatment in some patients [3] but also as a temporizing measure, facilitating stabilization of very sick infants for a subsequent laparotomy before or after transfer to a pediatric surgical center [1,2].Two multicenter randomized controlled trials comparing survival after primary peritoneal drainage or primary laparotomy have recently been published [4,5] Neither trial reached the recruitment target nor showed a significant benefit from drain or laparotomy. A meta-analysis of these 2 trials indicates no clear benefit from either treatment [4]. A third randomized controlled trial has been initiated in the United States (ClinicalTrials.gov Identifier: NCT01029353) with the primary outcome of death or neurodevelopmental impairment at 18 to 22 months of corrected age. Unless this current trial shows a dramatically different result from the others, it would seem unlikely that peritoneal drainage has a role in the future as a definitive treatment in NEC.
机译:穿孔性坏死性小肠结肠炎(NEC)婴儿的原发性腹膜引流已使用多年[1-3]。儿科医生将腹腔引流作为某些患者的确定性治疗[3],也是一种临时性措施,有助于稳定重病婴儿的稳定性,以便在转移至儿科手术中心之前或之后进行随后的剖腹手术[1,2]。两个多中心最近发表了比较原发性腹膜引流或原发性剖腹手术后生存率的随机对照试验[4,5],两项试验均未达到募集目标,也未显示从引流或剖腹术中获得显着获益。对这2项试验的荟萃分析表明,两种治疗均无明显获益[4]。美国已经启动了第三项随机对照试验(ClinicalTrials.gov标识符:NCT01029353),其主要结果是在校正年龄的18至22个月内死亡或神经发育受损。除非当前的试验显示出与其他试验截然不同的结果,否则腹膜引流作为NEC的最终治疗方法在未来似乎不太可能发挥作用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号